Figure 2.
Figure 2. Time course of bid expression after CD40 ligation on CLL B cells. In panel A the CLL cells were cocultured 1 day with HeLa cells or HeLa-CD154 that expressed the CD40 ligand. The CLL cells were separated from the adherent HeLa cells, cultured separately, and then used to prepare whole-cell lysates. Forty micrograms of cell lysate was applied to each lane of a polyacrylamide gel for immunoblot analyses with anti-Bid (top row) or anti–β-actin (bottom row), as indicated on the right side of the figure. The different lanes are of lysates prepared from CLL cells cultured for 1 day after coculture with HeLa cells (lane 1) or for 1 day (lane 2), 2 days (lane 3), or 4 days (lane 4) after coculture with HeLa-CD154 cells. In panel B, CLL cells were isolated from a patient before (lane 1), 1 day after (lane 2), or 14 days after (lane 3) infusion of 1 × 109 Ad-CD154–transduced autologous leukemia cells, as described.1 Forty micorgrams of cell lysate was applied to each lane for immunoblot analysis, as described in panel A.

Time course of bid expression after CD40 ligation on CLL B cells. In panel A the CLL cells were cocultured 1 day with HeLa cells or HeLa-CD154 that expressed the CD40 ligand. The CLL cells were separated from the adherent HeLa cells, cultured separately, and then used to prepare whole-cell lysates. Forty micrograms of cell lysate was applied to each lane of a polyacrylamide gel for immunoblot analyses with anti-Bid (top row) or anti–β-actin (bottom row), as indicated on the right side of the figure. The different lanes are of lysates prepared from CLL cells cultured for 1 day after coculture with HeLa cells (lane 1) or for 1 day (lane 2), 2 days (lane 3), or 4 days (lane 4) after coculture with HeLa-CD154 cells. In panel B, CLL cells were isolated from a patient before (lane 1), 1 day after (lane 2), or 14 days after (lane 3) infusion of 1 × 109 Ad-CD154–transduced autologous leukemia cells, as described.1 Forty micorgrams of cell lysate was applied to each lane for immunoblot analysis, as described in panel A.

Close Modal

or Create an Account

Close Modal
Close Modal